The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Injectable Drug Delivery Devices Market Grow Between 2026 And 2030?
The injectable drug delivery devices market has demonstrated substantial expansion in recent years. Its valuation is anticipated to climb from $54.3 billion in 2025 to $58.69 billion in 2026, advancing at a compound annual growth rate (CAGR) of 8.1%. The market’s past growth was primarily driven by the increasing occurrence of chronic diseases, the growth of biologics and biosimilars, a surge in hospital-based injectable treatments, enhancements in sterile manufacturing processes, and the wider availability of injection devices.
The injectable drug delivery devices market is projected to experience robust expansion in the coming years, reaching a valuation of $79.51 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period is fueled by several factors, including a growing preference for self-administration devices, an escalating need for customized drug delivery, the enlargement of biologic drug pipelines, increased capital expenditure in intelligent injection technologies, and the wider acceptance of home healthcare solutions. Key trends identified for this period encompass the increased uptake of prefilled and safety syringes, a surge in the demand for autoinjectors and pen injectors, the expanding application of injectable treatments administered at home, the development of wearable and implantable infusion pumps, and an amplified emphasis on precise dosing and patient well-being.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2835&type=smp
What Significant Factors Are Influencing The Injectable Drug Delivery Devices Market Expansion?
The increasing incidence of chronic illnesses is anticipated to propel the expansion of the injectable drug delivery devices market. A chronic disease is defined as a persistent ailment, enduring for three months or longer, with the potential to worsen over time. These devices provide a dependable and user-friendly approach for administering medications across prolonged durations. Such devices are capable of improving patient compliance with prescribed treatments, thereby ensuring efficient management of chronic conditions and ultimately yielding superior health results. For example, data from June 2024, published by the National Health Service, a UK government agency, revealed that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state characterized by higher-than-normal blood sugar, but not yet diabetes) in 2023. This represented an 18% rise from 3,065,825 instances recorded in 2022. Consequently, the growing occurrence of chronic illnesses is fostering the expansion of the injectable drug delivery devices market moving ahead.
How Is The Injectable Drug Delivery Devices Market Segmented Across Different Segment Categories?
The injectable drug delivery devices market covered in this report is segmented –
1) By Type: Syringes, Injectors, Pump
2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Other Applications
3) By End-user: Hospitals And Clinics, Home Healthcare Settings, Pharmaceutical And Biotechnological Companies, Research Laboratories, Other End Users
Subsegments:
1) By Syringes: Conventional Syringes, Prefilled Syringes, Safety Syringes
2) By Injectors: Autoinjectors, Pen Injectors, Needle-Free Injectors
3) By Pumps: Insulin Pumps, Ambulatory Infusion Pumps, Implantable Pumps
What Trends Are Affecting The Direction Of The Injectable Drug Delivery Devices Market?
Leading firms within the injectable drug delivery devices sector are prioritizing the creation of sophisticated solutions, including wearable and smart injectors, with the aim of boosting patient convenience, improving adherence, and facilitating the self-administration of intricate therapies. These wearable and smart injectors represent groundbreaking systems, engineered to administer precise dosages of medications, such as biologics and large-volume formulations, concurrently diminishing discomfort, lowering the potential for user error, and elevating the comprehensive treatment experience. As an illustration, in January 2025, Becton, Dickinson and Company, a medical technology firm based in the US, unveiled several next-generation devices, specifically including the BD Accuspray Nasal Spray System, BD Hylok Glass Prefillable Syringe, BD Effivax Glass Prefillable Syringe, BD Libertas Wearable Injector, BD Evolve On-body Injector, BD Physioject Disposable Autoinjector, and BD Vystra Disposable Pen. These particular solutions incorporate user-friendly designs for ease of self-administration, offer precise and consistent dosing for biologics and vaccines, maintain compatibility with various drug formulations, and come in wearable formats capable of supporting large-volume delivery, simultaneously guaranteeing sterility and safety through their disposable constituents. This introduction highlights the industry’s evolving direction towards sophisticated, patient-focused injectable drug delivery systems, intended to enhance adherence, increase comfort, and optimize therapeutic results.
Which Organizations Play A Role In The Injectable Drug Delivery Devices Market Landscape?
Major companies operating in the injectable drug delivery devices market are Becton Dickinson and Company, Baxter International, Gerresheimer AG, Catalent Inc., Antares Pharma, Owen Mumford, West Pharmaceutical Services Inc., B. Braun Melsungen AG, Ypsomed AG, AptarGroup Inc., Nemera, Teleflex Medical, Medtronic, Caplin Steriles Limited, Hovione Technology, Jiangsu Delfu Medical Device Co. Ltd., Terumo Corporation, Roche, Sorrel Medical, Novo Nordisk
Get The Full Injectable Drug Delivery Devices Market Report:
Where Is The Injectable Drug Delivery Devices Market Most Concentrated Geographically?
North America was the largest region in the injectable drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Injectable Drug Delivery Devices Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=2835&type=smp
Browse Through More Reports Similar to the Global Injectable Drug Delivery Devices Market 2026, By The Business Research Company
Glucose Biosensors Market Report 2026
https://www.thebusinessresearchcompany.com/report/glucose-biosensors-global-market-report
Disposable Medical Sensors Market Report 2026
https://www.thebusinessresearchcompany.com/report/disposable-medical-sensors-global-market-report
Disposable Medical Devices Sensors Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model